Lv51
1124 积分 2023-08-14 加入
Population Pharmacokinetic Modeling and Exposure-Response Analysis for the Antibody-Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma
1个月前
已完结
26-A-11834-ACC ART101 A SIRNA TARGETING ANGIOTENSINOGEN DEMONSTRATES DURABLE TARGET INHIBITION AND BLOOD PRESSURE LOWERING IN HEALTHY SUBJECTS
1个月前
已关闭
Abstract 4362610: Safety, Pharmacokinetics, and Pharmacodynamics of SGB-3908, A siRNA Targeting AGT in Healthy and Mildly Hypertensive Subjects
1个月前
已关闭
Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic end points
1个月前
已完结
Statistical issues in a modeling approach to assessing bioequivalence or PK similarity with presence of sparsely sampled subjects
1个月前
已完结
Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken
1个月前
已完结
Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates
2个月前
已完结
Likelihood based approaches to handling data below the quantification limit using NONMEM VI
2个月前
已完结
Impact of censoring data below an arbitrary quantification limit on structural model misspecification
2个月前
已完结
Ways to Fit a PK Model with Some Data Below the Quantification Limit
2个月前
已完结
皖公网安备34019202002308
